
    
      This study will evaluate DS-1062a 6.0 mg/kg vs docetaxel 75 mg/m^2 in participants with
      advanced or metastatic NSCLC without actionable genomic alterations and who have been
      previously treated with platinum-based chemotherapy and α-PD-1/α-PD-L1 monoclonal antibody,
      either in combination or sequentially. The study will be divided into 3 periods: Screening
      Period, Treatment Period, and Follow-up Period.
    
  